Company profile for Genenta Science

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug. Genenta has obtained regulatory...
We develop a gene transfer strategy into hematopoietic cells to target specific anti-tumor proteins. A definite vector delivers the gene into the cells. We use a combination of transcriptional and mediated control gene expression to selectively direct the anti-tumor proteins to the tumor area. Based on our exclusive mechanism, the immune system cells are reactivated and armed with a potent drug. Genenta has obtained regulatory approvals to initiate Phase I/II clinical trials in Multiple Myeloma patients with early relapse after front line therapy and newly diagnosed Glioblastoma Multiforme patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Italy
Address
Address
Via Olgettina 58 20132 Milano
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/19/3208308/0/en/Genenta-Science-Provides-Update-on-CEO-Ownership.html

GLOBENEWSWIRE
19 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193229/0/en/Genenta-Reports-Long-Term-Survival-Trends-and-Immune-Findings-in-Brain-Tumor-GBM-Trial.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/10/27/3174282/0/en/Genenta-Announces-Pricing-of-15-0-Million-Registered-Direct-Offering-of-American-Depositary-Shares.html

GLOBENEWSWIRE
26 Oct 2025

https://www.globenewswire.com/news-release/2025/10/24/3172648/0/en/Genenta-and-Anemocyte-Announce-Strategic-Partnership-to-Advance-Off-The-Shelf-LVV-Plasmid-DNA-Production.html

GLOBENEWSWIRE
24 Oct 2025

https://www.globenewswire.com/news-release/2025/07/01/3108119/0/en/Genenta-Announces-Long-Term-Follow-Up-Observations-in-Brain-Tumor-GBM-Study-with-Emerging-Survival-Signals.html

GLOBENEWSWIRE
01 Jul 2025

https://www.globenewswire.com/news-release/2025/05/07/3075936/0/en/Genenta-and-Anemocyte-announce-a-collaboration-for-the-manufacturing-of-starting-materials-for-cutting-edge-cell-based-therapies.html

GLOBENEWSWIRE
07 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty